(Q37862262)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21470070%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

review article

1 reference

title

How to treat patients with relapsed/refractory multiple myeloma: evidence-based information and opinions (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21470070%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21470070%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Massimo Offidani

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21470070%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

7

Antonio Palumbo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21470070%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

author name string

Laura Corvatta

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21470070%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Fortunato Morabito

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21470070%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Massimo Gentile

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21470070%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Pietro Leoni

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21470070%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

language of work or name

English

0 references

publication date

7 April 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21470070%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Investigational Drugs

27 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21470070%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

volume

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21470070%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21470070%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

page(s)

779-793

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21470070%20AND%20SRC:MED&resulttype=core&format=json

Improved survival in multiple myeloma and the impact of novel therapies

27 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.575060

Long-term outcome in relapsed and refractory multiple myeloma treated with thalidomide. Balancing efficacy and side-effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.575060

The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.575060

Bortezomib plus dexamethasone is highly effective in relapsed and refractory myeloma patients but responses are short-lived.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.575060

Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.575060

Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.575060

Treatment of newly diagnosed myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.575060

How to treat elderly patients with multiple myeloma: combination of therapy or sequencing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.575060

Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.575060

BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.575060

Impact of additional cytoreduction following autologous SCT in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.575060

Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.575060

Stem cell transplantation in multiple myeloma: impact of response failure with thalidomide or lenalidomide induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.575060

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.575060

Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.575060

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.575060

Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.575060

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.575060

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.575060

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.575060

Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.575060

Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.575060

Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.575060

Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.575060

Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.575060

Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.575060

Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.575060

Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.575060

Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.575060

Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.575060

Clinical course of patients with relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.575060

Value of combined androgen blockade in the neoadjuvant treatment of localized prostate cancer: the jury must remain out.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.575060

Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.575060

Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.575060

Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.575060

Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.575060

Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.575060

Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.575060

Thalidomide and hematopoietic-cell transplantation for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.575060

Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.575060

VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.575060

Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.575060

TC-PTP is required for the maintenance of MYC-driven B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.575060

Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.575060

Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.575060

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.575060

A novel proteasome inhibitor NPI-0052 as an anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.575060

CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.575060

Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.575060

Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.575060

The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.575060

Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.575060

The thalidomide analogue, CC-4047, induces apoptosis signaling and growth arrest in childhood acute lymphoblastic leukemia cells in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.575060

Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.575060

Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.575060

Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and predniso

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.575060

Novel therapies for relapsed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.575060

The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.575060

How I treat elderly patients with myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.575060

10.1517/13543784.2011.575060

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21470070%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

1 reference